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Abstract 
Exposure of precision-cut rat liver slices to six structurally diverse polycyclic 
aromatic hydrocarbons, namely benzo[a]pyrene, benzo[b]fluoranthene, 
dibenzo[a,h]anthracene, dibenzo[a,l]pyrene, fluoranthene and 1-methylphenanthrene, 
led to induction of ethoxyresorufin O-deethylase, CYP1A apoprotein and CYP1A1 
mRNA levels, but to a markedly different extent. In liver slices, constitutive CYP1A1 
mRNA levels were higher, as well as being markedly more inducible by PAHs, 
compared with CYP1B1, a similar profile to that observed in human liver slices 
following exposure to the PAHs. Increase in ethoxyresorufin O-deethylase and in 
CYP1A1 apoprotein levels was also observed when precision-cut rat lung slices were 
incubated with the same PAHs, the order of induction potency being similar to that 
observed in liver slices. Under the same conditions of exposure, CYP1B1 apoprotein 
levels were elevated in the lung. Up-regulation of CYP1A1 by the six PAHs 
correlated with their affinity for the Ah receptor, determined using the chemical-
activated luciferase expression (CALUX) assay. It may be concluded that: (a) 
precision-cut liver and lung slices may be used to assess the CYP1 induction potential 
of chemicals at the activity, apoprotein and mRNA levels; (b) rat is a promising 
surrogate animal for human in studies to evaluate CYP1 induction potential; (c) 
CYP1A1 is far more inducible than CYP1B1 in both rat liver and lung; (d) CYP1 up-
regulation by PAHs is related to their affinity for the Ah receptor, and finally (e) 
computer analysis revealed that the ratio of molecular length/width is an important 
determinant of CYP1 induction potency among equi-planar PAHs.  
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Introduction 
 
Polycyclic aromatic hydrocarbons (PAHs) comprise one of the largest and most 
ubiquitous classes of environmental chemical carcinogens. The major sources of 
human exposure are diet, as these are formed during domestic cooking, air and 
tobacco smoking (Skog and Jägerstad, 1998). They are indirect-acting genotoxic 
carcinogens in that they manifest their carcinogenicity through reactive intermediates 
that are produced following metabolic activation catalysed in many tissues, but most 
prominently in the liver. 
The principal pathway of metabolic activation of PAHs proceeds through an 
initial cytochrome P450-mediated bioactivation to generate epoxides which are 
converted to the corresponding trans-dihydrodiols by epoxide hydrolase; finally, a 
second oxidation, also catalysed by cytochromes P450, yields the dihydrodiol-
epoxide, the ultimate carcinogen (Conney, 1982). The cytochrome P450 family 
responsible for the metabolism, including bioactivation, of PAHs is CYP1, in 
particular CYP1A1 and CYP1B1 (Shimada and Fujii-Kuriyama, 1995; Ioannides and 
Lewis, 2004). Both of these enzymes are constitutively poorly expressed in the liver, 
and are essentially extrahepatic enzymes (Guengerich, 1990; Bhattacharyya et al., 
1995). CYP1, however, is probably the most inducible CYP family, at least in terms 
of induction observed, being up-regulated by planar compounds in the liver and 
extrahepatic tissues of animals and humans (Ioannides and Parke, 1990; Christou et 
al., 1995). This up-regulation of CYP1 is regulated by the Ah (aryl hydrocarbon) 
receptor, and a number of studies have shown that CYP1-inducing PAHs are good 
ligands for this receptor (Cheung et al., 1993; Machala et al., 2001; Piskorska-
Plizczynska et al., 1986).  
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The current studies were conducted in precision-cut slices in order to facilitate 
the use of human tissue. The advantages of adopting this in vitro system, in 
comparison with other systems such as subcellular fractions and primary hepatocytes, 
have frequently been pointed out in reviews (de Kanter et al., 1999; Lerche-Langrand 
and Toutain, 2000). Slices have been prepared from a number of tissues including 
liver (Hashemi et al., 1999), lung (Umachandran et al., 2004), intestine and colon (van 
de Kerkhof et al., 2005). 
The objectives of the present study were to: (a) assess the ability of six 
structurally diverse PAHs to up-regulate the two CYP1 enzymes involved in their 
metabolism, namely CYP1A1/B1, in the liver and lung, the principal site of their 
bioactivation and a target tissue respectively; (b) establish whether precision-cut liver 
slices can be used to assess the potential of PAHs to modulate CYP1A1/B1; (c) 
evaluate whether rat is an appropriate surrogate animal for human in such studies by 
investigating the ability of the same series of PAHs to modulate CYP1A1 in human 
liver slices; (d) investigate whether up-regulation of the same enzyme systems 
involves transcriptional activation mediated through the Ah receptor, and finally (e) 
through computer analysis identify structural characteristics that are associated with 
the induction of the CYP1 enzymes. 
 
Materials and methods 
Materials  
Dibenzo[a,l]pyrene, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1-
methylphenanthrene (LGC Promochem, Middlesex, UK), rat genomic DNA 
(Novagen, Wisconsin, USA), RNase-free DNase, cell culture lysis reagent, luciferase 
assay reagent (Promega, Wisconsin, USA), NADPH, sulphatase, β-glucuronidase, β-
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naphthoflavone, benzo[a]pyrene, fluoranthene, benzo[b]fluoranthene, 
dibenzo[a,h]anthracene, ethoxyresorufin, resorufin, 7-ethoxycoumarin, peroxidase-
linked anti-rabbit, anti-goat and anti-sheep antibodies (Sigma Co. Ltd., Poole, Dorset, 
UK), Qiagen RNeasy Mini kits (Crawley, West Sussex, UK), AbsoluteTM QPCR Mix 
(Abgene, Epsom, Surrey, UK), and Earle’s balanced salt solution (EBSS), foetal calf 
serum, gentamycin, hexamers, Superscript II and RPMI 1640 with L-glutamine 
culture medium (Invitrogen, Paisley, Scotland) were all purchased. Twelve-well 
plates were obtained from Bibby Sterilin (Helena Biosciences, Sunderland, UK). Rat 
anti-CYP1A1, recognising both CYP1A1 and CYP1A2, and anti-CYP1B1 antibodies 
were obtained from BD Biochemicals (Oxford, UK).  
 
Preparation and incubation of precision-cut tissue slices 
Liver sections from two human cadaveric livers that could not be used for 
transplantation purposes were obtained from the UK Human Tissue Bank (The 
Innovation Centre, Oxford Street, Leicester, U.K). Donor 1 was a 60-year old male 
and Donor 2 a 57-year old female; both were Caucasian and smokers. Sections were 
received 8 - 12 hours after the liver was removed from the donor and were transported 
in cold University of Wisconsin (UW) preservation solution on ice.  On receipt, the 
liver sections were immediately transferred into a sterile container and, after the UW 
solution was carefully decanted, they were washed 3 to 4 times with culture medium.  
Slices were prepared as with rat liver (vide infra) and pre-incubated for 30 minutes 
prior to the start of the experiment, to allow equilibrium to be reached and ensure 
complete removal of the transport buffer. Metabolic viability was evaluated using 7-
ethoxycoumarin as substrate, following a 6-hour incubation (vide infra).  Male Wistar 
albino rats (200g) were obtained from B&K Universal Ltd (Hull, East Yorkshire, 
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UK). The animals were housed at 22 ± 2 °C, 30-40 % relative humidity in an 
alternating 12-hr light:dark cycle with light onset at 07.00 hr. Rats were killed by 
cervical dislocation, and liver was immediately excised. In the in vivo study, rats were 
treated with a single intraperitoneal dose of either β-naphthoflavone or 
benzo[a]pyrene (25 mg/kg) and were killed 24 hours afterwards. 
Rat and human liver slices (250 μm) were prepared from 8mm cylindrical 
cores using a Krumdieck tissue slicer (Alabama Research and Development 
Corporation, Munsford, AL, USA) as previously described (Hashemi et al., 1999). 
The multiwell plate procedure, using 12-well culture plates, was used to culture the 
slices. One slice was placed in each well, in 1.5 ml of culture medium. Slices were 
incubated under sterile conditions on a reciprocating plate shaker housed in a 
humidified incubator, at a temperature of 37 ºC and under an atmosphere of 95 % 
air/5% CO2. The slices were initially pre-incubated for 30 min in order to slough off 
any dead cells due to slicing. For the production of lung slices, animals were killed by 
an overdose of sodium pentobarbital, and lungs were perfused intratracheally with 
agarose (0.75% v/w) at 37 °C. Agar was allowed to solidify, and lung slices (600 μm) 
were prepared from cylindrical cores (8 mm) as described for the liver (Umachandran 
et al., 2004, 2006). A pre-incubation of 60 minutes was carried out. For incubations 
exceeding 24 h, slices were placed in fresh medium every 24 h. Three different slice 
pools, comprising 4-10 slices, were used per time point. 
 
Enzyme assays 
Following incubation, slices were removed from the medium, homogenised, and 
microsomal fractions were prepared by differential centrifugation. The O-deethylation 
of ethoxyresorufin (Burke and Mayer, 1974) was determined in hepatic microsomes, 
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but in the lung studies activity was determined in the post-mitochondrial fraction (S9), 
as it was more facile to determine the low levels of activity in lung slices following a 
24-hour incubation; in this instance the incubation system was supplemented with 
dicoumarol (8 μM) in order to inhibit cytosolic quinone reductase (Price et al., 2004). 
Protein concentration was determined in both fractions (Bradford, 1976). Finally, in 
order to determine apoprotein levels, hepatic microsomal proteins were resolved by 
electrophoresis and incubated with the primary antibody and the corresponding 
peroxidase-linked secondary antibody. Immunoblots were quantitated by 
densitometry using the GeneTool software (Syngene Corporation, Cambridge, UK). 
In preliminary studies, a linear response was established with protein levels ranging 
50 to 400 μg of protein (results not shown).  
 
Transcript level measurement 
Two slices were used for total RNA extraction, and for each sample triplicates were 
carried out. RNA was extracted using the Qiagen RNeasy Mini kit and was quantified 
using a Nanodrop spectrophotometer. Total RNA was treated with RNase-free DNase 
to remove genomic contamination. Reverse transcription was primed with random 
hexamers and carried out by Superscript II according to the manufacturer’s 
instructions. To ensure that DNase-treated samples were free from genomic 
contamination, an RT- control was carried out for every RNA sample. cDNA 
generated from 50ng was amplified using AbsoluteTM QPCR Mix with 400 nM 
primers and 100 nM fluorogenic probe in a total reaction volume of 25μl. Q-PCR 
reactions were run on the ABI7000 SDS instrument (Applied Biosystems, 
Warrington, UK) and quantitation was carried out using the ABI proprietary software 
against a standard curve generated from rat genomic DNA. 
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For the quantitative reverse transcription-polymerase chain reaction, the 
primers and TAMRA/FAM dual labelled probes (Table 1) were designed using the 
Primer Express software (Applied Biosystems) and purchased from MWG, 
Ebersberg, Germany.  Each primer and probe set was designed to amplify sequences 
within a single exon, so that genomic DNA could be used as a standard.  
 
Metabolism of 7-ethoxycoumarin by precision-cut human liver slices 
The metabolism of 7-ethoxycoumarin (50 μM) by human liver slices to 7-
hydroxycoumarin and to its sulphate and glucuronide conjugates was monitored as 
described by Steensma et al. (1994). For the determination of the conjugates, aliquots 
of the media were diluted with a half-volume of 0.5 M sodium acetate buffer (pH 5), 
containing either β-glucuronidase (5000 Units/ml) or sulphatase (250 Units/ml) 
containing the β-glucuronidase inhibitor D-saccharic acid 1,4-lactone (17mM). The 
mixtures were incubated for 16 h at 37 °C, and the free 7-hydroxycoumarin was 
determined as follows. Aliquots (0.3 ml) of the incubation media, before and after 
deconjugation, were made to 1 ml with 0.154 M KCl buffer containing 50 mM Tris-
HCl, pH 7.4. Following addition of 4M HCl (0.25 ml), the samples were extracted for 
30 min with chloroform (6 ml) on a rotary mixer. Aliquots (5 ml) of the chloroform 
layer were subsequently extracted for a further 30 min with 3ml of 0.5 M glycine-
NaOH buffer, pH 10.5. The fluorescence of the aqueous layer was measured using 
excitation and emission wavelengths of 380 and 452 nm respectively. Standards of 7-
hydroxycoumarin were run through the same procedure. Finally, slices were 
homogenised in  0.154 M KCl buffer containing 50 mM Tris-HCl, pH 7.4, and total 
protein was determined using bovine serum albumin as standard (Bradford, 1976).  
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AhR ligand-binding assay 
Interactions of the PAHs with the Ah receptor were assessed using the chemical-
activated luciferase expression (CALUX) assay. In 24-well plates, H1L1.1c2 cells 
were cultured (7 x 104 cells/ml) in α-MEM (minimum essential medium) 
supplemented with 10% FBS and penicillin-streptomycin-neomycin antibiotic 
solution; cells were cultured for 24 hours until 50-70 % confluent. Cells were then 
incubated with a range of concentrations of PAHs, dissolved in DMSO, for 24 hours 
at 37°C and 5 % CO2 in a humid environment, and subsequently washed with PBS; an 
aliquot of the cell culture (100 μl) was incubated for 15 minutes with the lysis reagent. 
Cell lysates were centrifuged at 13000g for 2 minutes, and luciferase activity in the 
supernatant was determined using the Promega stabilised luciferase assay reagent 
according to the manufacturer’s instructions. Luminescence was read in a Packard 
Lumicount microplate luminometer with PlateReader software (Packard Instrument 
Company). TCDD (10-9 M) served as a positive control, achieving 100 % binding. 
 
In silico molecular analysis 
Electronic structural parameters were determined using the AM1 molecular orbital 
method based on previously minimised molecular structures.  Molecular shape 
parameters (area/depth2 and length/width) were produced from the dimensions 
(length, width and depth) of each molecule as described previously (Lewis, et al., 
1998; 2002).  All structural calculations were conducted on the Sybyl 7.0 (Tripos 
Associates, St. Louis, MO) molecular modelling suite of programs operating under 
Linux. 
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Statistical evaluation 
Statistical evaluation was carried out using the Student’s t-test. 
 
 
Results 
The structures of the PAHs employed in the current study are shown in Figure 1.  
 
Rat liver studies 
Following exposure of rat liver slices to a range of concentrations (1-100 μM) of 
PAHs for 24 hours, the O-deethylation of ethoxyresorufin was markedly induced by 
benzo[a]pyrene and dibenzo[a,h]anthracene, maxima being achieved at about 10 μM; 
extent of induction declined at higher concentrations (Figure 2). In the case of 
benzo[b]fluoranthene it was observed that maximum induction had already been 
achieved at the lowest concentration used i.e. 1 μM (results not shown) so an 
additional study was undertaken utilising a lower range of concentrations (0.25-1 
μM); a concentration-dependent increase in ethoxyresorufin O-deethylase was 
observed (Figure 2). Finally, 1-methylphenanthrene and fluoranthene failed to 
modulate this enzyme activity whereas dibenzo[a,l]pyrene caused significant, but 
modest , increase only at the 10 μM concentration (Figure 2). 
 Immunoblot analysis following probing of microsomes with rat anti-CYP1A1, 
showed that the changes in ethoxyresorufin O-deethylase following exposure to 
benzo[a]pyrene, benzo[b]fluoranthene and dibenzo[a,h]anthracene were paralleled by 
similar changes in apoprotein levels, and a less pronounced rise in apoprotein levels 
was seen with dibenzo[a,l]pyrene (Figure 3). Fluoranthene also showed a rise in 
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apoprotein levels, albeit at the higher concentrations, but 1-methylphenanthrene had 
no significant effect (Figure 3). 
 All PAHs studied led to an increase in CYP1A1 mRNA levels when incubated 
with precision-cut liver slices for 24 hours (Figure 4). A marked rise in mRNA levels 
was evident with benzo[a]pyrene, dibenzo[a,h]anthracene, benzo[b]fluoranthene and, 
to a lesser extent, dibenzo[a,l]pyrene at the lowest concentration studied, i.e. 0.1 μM, 
but in the case of fluoranthene and 1-methylphenanthrene concentrations of 5 and 10 
μM respectively were required for a statistically significant increase to be manifested 
(Figure 4). 
 As there is no selective substrate suitable for monitoring CYP1B1 activity 
(Murray et al., 2001), modulation of this activity in the lung was assessed at the 
apoprotein level. However, as a result of the poor expression of CYP1B1 in the liver 
(Bhattacharyya et al., 1995), apoprotein levels were difficult to detect, especially after 
incubation of slices for 24 hours during which cytochromes P450 decline (Hashemi et 
al., 2000), and was monitored at the mRNA level.When CYP1B1 mRNA levels were 
monitored, once again a rise was noted in liver slices exposed to all PAHs, with 
benzo[b]fluoranthene, benzo[a]pyrene and dibenzo[a,h]anthracene being the more 
potent (Figure 5). Constitutive levels of CYP1B1 mRNA levels were much lower 
compared with CYP1A1 (51 ± 5 copies per 50 ng RNA compared to 8623 ± 231 in 
the case of CYP1A1 mRNA). 
 
Rat lung studies  
Exposure of precision-cut rat lung slices to the various PAHs for 48 hours led to 
enhancement of ethoxyresorufin O-deethylase activity but, as observed in liver slices, 
there was marked difference in potency; benzo[a]pyrene, benzo[b]fluoranthene and 
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dibenzo[a,h]anthracene were the most effective, whereas dibenzo[a,l]pyrene was a 
modest inducer, and fluoranthene and 1-methylphenanthrene failed to significantly 
modulate this activity (Figure 6). In all cases induction maxima were reached at the 1 
μM concentration. 
 Immunoblot analysis employing antibodies to CYP1A1 revealed marked 
changes in the CYP1A1 apoprotein levels that paralleled activity, except in the case of 
1-methylphenanthrene where a relatively modest increase in apoprotein levels in the 
absence of a significant rise in ethoxyresorufin O-deethylase activity was observed 
(Figure 7). 
 When the immunoblot studies were conducted utilising antibodies to CYP1B1, 
only modest increases, compared with CYP1A1, in apoprotein levels were revealed 
when rat lung slices were incubated with the PAHs under identical conditions (Figure 
8). Benzo[a]pyrene, benzo[b]fluoranthene and dibenzo[a,h]anthracene were the most 
potent inducers, whereas fluoranthene and dibenzo[a,l]pyrene did not display a major 
effect. 1-Methylphenanthrene, however, elevated CYP1B1 apoprotein levels when 
incubated with the lung slices at high concentrations, as observed with CYP1A1.  
 
Human liver studies 
The described studies were conducted on two different occasions, i.e. using two 
different fresh liver samples. Liver metabolic viability of human slices was monitored 
using 7-ethoxycoumarin as the model substrate. Although both liver samples 
converted 7-ethoxycoumarin to the sulphate and glucuronide conjugates of 7-
hydroxycoumarin, the rate of metabolism of the liver from donor 1 was double that of 
donor 2 (Figure 9); donor 1 also displayed higher ethoxyresorufin O-deethylase 
activity. However, when slices from both livers were exposed to benzo[a]pyrene, 
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induction potency per μmole of ethoxyresorufin O-deethylase was similar, being 6.58  
and 6.02 for donors 1 and 2 respectively (results not shown). Exposure of liver slices 
to PAHs modulated ethoxyresorufin O-deethylase activity; the most potent inducers 
were benzo[a]pyrene, dibenzo[a,h]anthracene whereas dibenzo[a,l]pyrene and 
fluoranthene displayed a relatively modest effect, and 1-methylphenanthrene had no 
significant effect (Figure 10). In the case of benzo[b]fluoranthene maximum elevation 
in enzyme activity appears to have been attained at a concentration of 1 μM, the 
lowest concentration studied.  Immunoblot analysis revealed similar changes in 
apoprotein levels (Figure 11). 
 
Ex-vivo study 
Antibodies to CYP1B1 immunoreacted with a single band in both rat liver and lung 
microsomes. Treatment with benzo[a]pyrene elevated apoprotein levels only in the 
lung whereas β-naphthoflavone had no effect in either tissue at this dose level (Figure 
12) 
 
Binding to the Ah receptor 
The six PAHs differed markedly in their ability to bind to the Ah receptor, with EC50 
values covering at least four orders of magnitude. Benzo[a]pyrene, 
dibenzo[a,h]anthracene and, especially, benzo[b]fluoranthene were the best ligands 
(Figure 13, Table 2), whereas 1-methylphenanthrene exhibited no significant binding.  
 
Computer analysis 
Table 3 lists the molecular and electronic parameters of the six PAHs used in this 
study, which have been employed to identify correlations with CYP1 induction 
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potency. With the exception of 1-methylphenanthrene, all PAHs were planar 
compounds having the same depth (D) and characterised by a large a/d2 value. 
 
Discussion 
The conditions of exposure of slices to PAHs were based on our previous studies 
(Pushparajah et al., 2007). When CYP1 was monitored at the activity level, using 
ethoxyresorufin as probe substrate, a marked difference in the ability of the six PAHs 
to elevate this activity in rat liver slices was noted. The present findings mirror 
observations in Ah-responsive mice following treatment with a series of PAHs where 
benzo[b]fluoranthene and dibenzo[a,h]anthracene were among the most potent 
inducers of ethoxyresorufin O-deethylase, benzo[a]pyrene was also a good inducing 
agent, more effective than dibenzo[a,l]pyrene, whereas fluoranthene was poor 
(Shimada et al., 2003). Moreover, the present observations make a case for using 
precision-cut liver slices for assessing induction potential of slices, rather than in vivo 
studies, which not only allow the facile use of many concentrations but also minimise 
the number of animals. The rise in activity was accompanied by elevation in 
apoprotein levels indicating that increased enzyme availability is, at least in part, 
responsible for the enhanced activity. Increased transcription, as evidenced by a rise 
in CYP1A1 mRNA levels, is likely to contribute to the enhanced enzyme synthesis. 
All PAHs studied elevated mRNA levels albeit to a different extent, but an increase in 
protein levels and ethoxyresorufin O-deethylase activity were observed with the most 
potent inducers. It has been suggested that a threshold exists that has to be exceeded 
in order for mRNA to be translated, so that activation of the gene at the mRNA level 
does not always lead to higher protein levels, and concords with the data presented 
herein (Greenbaum et al., 2003). In recent studies, in agreement with the present 
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findings, where HepG2 cells and liver slices were exposed to the same series of PAHs 
and changes in gene expression were assessed using cDNA microarrays and 
oligonucleotide microarrays respectively, an increase in CYP1A1 gene expression was 
noted for all compounds except 1-methylphenathrene; the most potent were 
benzo[a]pyrene, benzo[b]fluoranthene and dibenzo[a,h]anthracene (Staal et al., 2006, 
2007). 
A picture shared by all PAH inducers of ethoxyresorufin O-deethylase is that 
activity decreased at concentrations exceeding those at which maximum induction 
occurred, although it was still higher than control, and a similar picture emerged when 
CYP1A apoprotein or mRNA levels were determined. Similar observations have been 
reported by other workers where exposure of rat liver slices to benzo[a]pyrene caused 
a more pronounced degree of induction of ethoxyresorufin O-deethylase at the lower 
concentrations studied (Price et al., 2004). A likely explanation is that at these high 
concentrations viability of slices is compromised leading to impairment of protein 
synthesis. It may be that the generation of toxic intermediates overwhelms 
detoxication enzyme systems, such as glutathione S-transferase, leading to 
compromised cellular defences and a rise in toxicity (Whitlock, 1999); it is pertinent 
to point out that the ethoxyresorufin O-deethylase-inducing PAHs, under identical 
conditions of incubation, cause only a very modest increase in glutathione S-
transferase activity which, thus, may not be able to compensate for the enhanced 
generation of oxides and quinones  (unpublished observations). However, loss in slice 
viability was observed by any of the PAHs, at the concentrations employed in the 
present study, as exemplified by the leakage of lactate dehydrogenase into the 
medium (results not shown). A likely contributory mechanism may involve inhibition 
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of CYP1A1 activity at the high concentrations of PAHs (Shimada and Guengerich, 
2006).  
 When human liver slices were likewise exposed to these PAHs, the observed 
induction profile was very similar to that noted in rat slices. Fluoranthene, however, 
caused a relatively weak increase in ethoxyresorufin O-deethylase activity in human 
slices, whereas in rat slices it was visible only at the apoprotein and mRNA levels. 
Immunoblot analysis revealed commensurate increases in apoprotein levels when 
microsomes were probed with antibodies to CYP1A1, indicating that once again a rise 
in enzyme levels is responsible for the increased ethoxyresorufin O-deethylase 
activity. However, in contrast to the rat, apoprotein levels did not drop at high PAH 
concentrations, implying that the decrease in activity observed at high PAH 
concentrations is due to inhibition rather than impaired enzyme synthesis. It is of 
interest that fluoranthene and dibenzo[a,l]pyrene, which do not or poorly suppress 
ethoxyresorufin O-deethylase respectively at high concentrations, are poor inhibitors 
of CYP1A1, whereas benzo[a]pyrene and benzo[b]fluoranthene, which suppress this 
enzyme activity, are strong inhibitors (Shimada and Guengerich, 2006). The close 
relationship in ethoxyresorufin O-deethylase induction following exposure of human 
and rat slices to PAHs implies that the human liver Ah receptor is similar to the rat 
counterpart, at least as far as ligand interaction and subsequent response are 
concerned, and supports the proposal that the Ah receptor is a highly conserved 
protein (Bank et al., 1992). Moreover, when hepatocytes were exposed to a series of 
PAHs, the order of CYP1A induction was the same, but degree of induction was 
double in rat compared with human (Vakharia et al., 2001; Till et al., 1999). It thus 
appears that although the affinity for the receptor and, consequently, CYP1A1 
inducibility can vary between rat and human, the order of potency for a series of 
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PAHs is the same, so that studies undertaken in rats to compare the CYP1A induction 
potential of a series of PAHs can be extrapolated to humans. 
Rat lung slices were exposed to the same PAHs, but for 48 hours and at a 
lower range of concentrations, based on our previous studies (Pushparajah et al., 
2007). As we have already reported, substantial variation in the O-deethylation of 
ethoxyresorufin between lung slices was noted, which most likely reflects the fact that 
the lung, in contrast to the liver, has a heterogeneous cell population, with xenobiotic-
metabolising activity being present only in some cell types (Hukkanen et al., 2002). 
However, it was up-regulated following exposure of the lung slices to the same series 
of PAHs, the order of induction being similar to that in liver slices. Clearly, what 
these studies indicate is that no tissue difference exists in CYP1A1 up-regulation by 
PAHs in rat. In general, extent of induction was more pronounced in the liver; 
however, maxima in the lung slices were achieved at 1 μM, whereas in the liver, in 
most cases, it necessitated a 10 μM concentration. This difference in concentration 
may reflect, at least partly, the higher rate of metabolic breakdown of PAHs such as 
benzo[a]pyrene in liver compared with lung, leading to a rapid decline in its effective 
concentration; the rate of metabolism of benzo[a]pyrene to phenolic products in liver 
slices is higher compared with lung slices (unpublished observations). Up-regulation 
of ethoxyresorufin O-deethylase activity in lung slices was accompanied by increase 
in CYP1A1 apoprotein levels indicating that also in this tissue rise in activity was 
most likely due to elevated enzyme synthesis Induction of ethoxyresorufin O-
deethylase activity declined in lung slices as witnessed in the liver. Concordant to 
these observations, it has been recently reported that CYP1A1 mRNA levels in lung 
slices treated with benzo[a]pyrene rose in a concentration-dependent manner up to 10 
μM, but dropped at higher concentrations (Harrigan et al., 2006). A good correlation 
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has been obtained in the induction of ethoxyresorufin O-deethylase activity in the 
liver and lung, showing that up-regulation of CYP1A is similar in these tissues 
(Figure 14). When CYP1A levels were monitored immunologically, a far more potent 
effect was witnessed in the lung. This can be attributed to the fact that the antibody 
recognises both CYP1A1 and A2, but the latter is only expressed in the liver so that 
control levels are much higher. 
Although the up-regulation of CYP1A1 by PAHs has been extensively studied 
(Ioannides and Parke, 1990), CYP1B1 received much less attention since it was 
discovered decades after CYP1A1 (Murray et al., 2001). It is a very important catalyst 
of the bioactivation of PAHs; of the three members of the CYP1 family, CYP1B1 was 
the most efficient in converting benzo[a]pyrene to its 7,8-diol, benzo[c]phenanthrene 
to its 3,4-dihydrodiol, the precursors of the ultimate carcinogens, dibenz[a]anthracene 
to the 3,4-oxide, the proximate carcinogen, and dibenzo[a,l ]pyrene to DNA-binding 
adducts (Shimada et al., 1996; Luch et al., 1998). All PAHs elevated CYP1B1 mRNA 
levels in the liver, but the extent of induction was drastically lower compared with 
CYP1A1 mRNA, indicating that the latter enzyme is far more inducible by this class 
of compounds in rat liver. Similar observations were made in rats following treatment 
with TCDD (Walker et al., 1998) and, moreover, exposure of rat liver and lung slices 
to benzo[a]pyrene led to a more marked increase in CYP1A1 mRNA levels compared 
with CYP1B1 mRNA (Harrigan et al.,  2004). Once again, dibenzo[a,h]anthracene, 
benzo[b]fluoranthene and benzo[a]pyrene were the most potent, with 
dibenzo[a,l]pyrene being the least potent; unexpectedly,  however, 1-
methylphenathrene was an effective inducer of  CYP1B1 mRNA levels. In the lung, 
with the exception of fluoranthene and dibenzo[a,l]pyrene, all other PAHs studied 
elevated CYP1B1 apoprotein levels. Once again, 1-methylphenanthrene caused a 
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marked increase in CYP1B1 apoprotein levels. This PAH is not a ligand for the Ah 
receptor and raises the possibility that an Ah-independent pathway for the regulation 
of CYP1B1 may exist (Murray et al., 2001). Indeed, it has already been reported that 
in Ah receptor knockout mice piperonyl butoxide raised CYP1B1, but not CYP1A1, 
mRNA levels (Ryu et al., 1996). Since changes in CYP1 expression following 
exposure to PAHs were monitored at the mRNA and protein level in the liver and 
lung respectively, thus not allowing direct comparison, a limited ex vivo study was 
conducted where animals were treated with benzo[a]pyrene, the prototype PAH, as 
well as β-naphthoflavone, an established CYP1 inducer. In both tissues a single 
immunoreacting band was detected but expression in the lung was more than double 
that of the liver. Moreover, exposure to β-naphthoflavone failed to up-regulate 
CYP1B1 apoprotein levels in both tissues whereas benzo[a]pyrene stimulated 
apoprotein levels in the lung but not liver; it may be cautiously inferred that PAHs as 
a class may be more potent inducers of CYP1B1 in the lung compared with the liver. 
Induction of CYP1 expression by the PAHs, in both human and rat tissues, 
paralleled the affinity of the PAH for the Ah receptor as previously shown using a 
series of chrysenes (Cheung et al., 1993) and, moreover, the rise in mRNA levels 
implies enhanced transcriptional activity. In vitro studies employing tissue slices offer 
an advantage over in vivo studies in establishing such correlations in that in the former 
approach tissue concentration is not influenced by pharmacokinetic processes such as 
absorption and pre-systemic metabolism. Inducers of the CYP1A subfamily are 
essentially planar molecules characterised by a low depth and high area/depth2 ratio, 
an index of planarity (Lewis et al., 1986). Of the six PAHs studied, only 1-
methylphenantrene is not completely planar because of the methyl substitution and 
this may explain its inability to ligand to the Ah receptor. However, even non-
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substituted tricyclic PAHs such as anthracene, pyrene and fluorene (Ayrton et al., 
1990; Shimada et al., 2002; Piskorska-Plizczynska et al., 1986; Machala et al., 2001) 
are poor ligands of the Ah receptor and at best weak CYP1A inducers, raising the 
possibility that molecular size is an important factor. For this reason, molecular size 
and electronic parameters were calculated for each PAH used in the current studies. 
No relationship could be found between any single electronic parameter calculated 
and CYP1A induction activity as exemplified by the O-deethylation of 
ethoxyresorufin. However, a good correlation has been obtained between CYP1A1 
inducibility in both liver and lung and the ratio of length/width even using this small 
number of compounds (Figure 15); PAHs with a small ratio were poor CYP1 inducers 
and ligands to the Ah receptor. Similar good correlation has been obtained between 
the same ratio and increase in hepatic CYP1A1 and CYP1B1 mRNA levels (Figure 
15). These observations are in agreement with our previous studies where 
benzo[a]pyrene and 2-acetylaminofluorene were good inducers of CYP1, whereas 
their isomers benzo[e]pyrene and 4-acetylaminofluorene, having a lower length/width 
ratio, were poor inducers of this enzyme (Lewis et al., 1994). It is relevant to point out 
that TCDD, the most avid ligand identified for the Ah receptor, has a length/width 
ratio of 1.889 and possibly reflects the optimum dimensions. 
 In conclusion, the current studies have confirmed that CYP1A induction can 
be monitored in lung and liver slices and, moreover, demonstrated that: (a) precision-
cut liver and lung slices can be used also to assess the inducibility of CYP1B1; (b) in 
rat liver and lung PAHs induce both CYP1A/CYP1B1, but to a markedly different 
extent; (c) at the mRNA level, hepatic CYP1A is far more inducible than CYP1B1 by 
PAHs; (d) CYP1 induction by PAHs is correlated to their ability to interact with the 
Ah receptor; (e) CYP1A1 activity is induced by PAHs to a similar extent in rat and 
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human liver slices indicating that the rat is an appropriate surrogate animal for human 
in such studies, and (f) in equiplanar PAHs, molecular dimensions are important 
factors in determining CYP1 up-regulation. 
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Table 1: Taq Man® primers and probes for rat CYP1A1 and CYP1B1 
 
The location is relative to position one of the accession number.  Probes were labelled with 5′ TAMRA and 
3’ FAM 
Gene Accession 
Number 
Location 5′ primer 3′ primer Probe 
CYP1A1 NM_ 
 
012540 
97 –122 GCCTTCACATCAGC 
 
CACAGA 
TTGTGACTCTAAC 
 
CACCCAGAATC 
 
TGGCCGTCACCA 
 
CATTCTGCCTT 
 
CYP1B1 NM_ 
 
012940 
 
2696 – 
 
2775 
TTCAGCTGTTCAAA 
 
CGAAGCA 
 
TCCCAAAGTTGA 
 
AGCTTACGTTA 
 
CGAGTTATGAGGGA 
 
GAAAAAGGTTTGCCA 
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Table 2: Ligand binding of the six PAHs to the Ah receptor 
 
Binding of the PAHs to the Ah receptor was performed using the CALUX assay. EC50 
values were determined graphically from plots of substrate concentration (M) vs 
binding to the Ah receptor expressed in terms of TCDD binding (10-9 M). 
 
 
Polycyclic aromatic hydrocarbon Ah receptor binding affinity 
EC50 (M) 
Benzo[b]fluoranthene 5 x 10-8 
Dibenzo[a,h]anthracene 5 x 10-7 
Benzo[a]pyrene 5 x 10-6 
Dibenzo[a,l]pyrene 15% at 10-4 
Fluoranthene  13% at 10-4 
1-Methylphenanthrene No binding 
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Table 3: Structural and electronic characteristics of the six polycyclic aromatic hydrocarbons 
 
L, Molecular length; W, Molecular width; D, Molecular depth; L/W, Ratio of molecular length to molecular width; a/d2, ratio of molecular area 
(l x w) to the square of depth; μ, dipole moment; EHOMO, Energy of the Highest Occupied Molecular Orbital; ELUMO, Energy of the Lowest 
Unoccupied Molecular Orbital; ΔE, EHOMO – ELUMO; IP, fold-increase in the O-deethylation of ethoxyresorufin/ μmol of compound. 
 
 
 L (Å) W(Å) D(Å) a/d2 L/W μ  
(Debye) 
EHOMO 
(eV) 
ELUMO 
(eV) 
ΔE IP 
Benzo[b]fluoranthene 13.642 9.541 3.200 12.709 1.430 0.606 -8.3824 -1.2520 7.1304 29.38 
Benzo[a]pyrene 12.871 9.452 3.200 11.881 1.362 0.049 -7.6442 -1.3703 6.2739 14.79 
Dibenzo[a,h]anthracene 13.970 9.458 3.200 12.903 1.477 0.002 -8.0476 -1.0143 7.0333 19.13 
Dibenzo[a,l]pyrene 13.674 11.887 3.200 15.978 1.158 0.209 -7.7544 -1.3276 6.4267 1.80 
Fluoranthene  11.302 9.541 3.200 10.531 1.185 0.511 -8.4298 -1.2244 7.2054 0.04 
1-methylphenanthrene 11.569 7.930 4.201 5.198 1.459 0.298 -8.3702 -0.5555 7.8147 0.02 
 
 
Legends to figures 
 
Figure 1: Structure of PAHs used in the study 
 
Figure 2: Concentration-dependent induction of ethoxyresorufin O-deethylase 
activity by PAHs in precision-cut rat liver slices. 
 
Precision-cut rat liver slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations for 24 hours. At the end of 
the incubation period, slices were removed from the media, microsomes prepared and 
ethoxyresorufin O-deethylase (EROD) activity determined. Results are expressed as 
mean ± SD of triplicate pools of slices. 
* P<0.05; ** P<0.01; *** P<0.001 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 3: Concentration-dependent changes in CYP1A1 apoprotein levels in 
precision-cut rat liver slices incubated with PAHs. 
 
Precision-cut rat liver slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations for 24 hours. At the end of 
the incubation period, slices were removed from the media, microsomes prepared and 
proteins resolved by 10% (w/s) SDS-PAGE before being transferred 
electrophoretically to nitrocellulose paper. Immunoblot was carried out with anti-rat 
CYP1A1 followed by peroxidase-labelled anti-goat IgG; all lanes were loaded with 5 
μg protein. Figures above the immunoblot represent percentage values compared with 
control (DMSO-treated) slices which were set at 100%. 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 4: Concentration-dependent changes in CYP1A1 mRNA levels in 
precision-cut rat liver slices incubated with PAHs. 
 
Precision-cut rat liver slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations for 24 hours. At the end of 
the incubation period, slices were removed from the media and total RNA extracted. 
CYP1A1 mRNA levels were determined by quantitative RT-PCR (TaqMan). Changes 
are shown as fold-increases compared to control slices incubated with DMSO only. 
Results are expressed as mean ± SD where n=4. 
*** P<0.001 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 5: Concentration-dependent changes in CYP1B1 mRNA levels in 
precision-cut rat liver slices incubated with PAHs. 
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Precision-cut rat liver slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations for 24 hours. At the end of 
the incubation period, slices were removed from the media and total RNA extracted. 
CYP1B1 mRNA levels were determined by quantitative RT-PCR (TaqMan). Changes 
are shown as fold-increases compared to control slices incubated with DMSO only. 
Results are expressed as mean ± SD where n=4. 
* P<0.05; ** P<0.01; *** P<0.001 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 6: Concentration-dependent induction of ethoxyresorufin O-deethylase 
activity by PAHs in precision-cut rat lung slices. 
 
Precision-cut rat lung slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations (0-5 μM) for 48 hours. At the 
end of the incubation period, slices were removed from the media, microsomes 
prepared and ethoxyresorufin O-deethylase (EROD) activity determined. Results are 
expressed as mean ± SD of triplicate pools of slices. 
* P<0.05; ** P<0.01; *** P<0.001 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 7: Concentration-dependent changes in CYP1A1 apoprotein levels in 
precision-cut rat lung slices incubated with PAHs. 
 
Precision-cut rat lung slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations (0-5 μM) for 48 hours. At the 
end of the incubation period, slices were removed from the media, microsomes 
prepared and proteins resolved by 10% (w/s) SDS-PAGE before being transferred 
electrophoretically to nitrocellulose paper. Immunoblot was carried out with anti-rat 
CYP1A1 followed by peroxidase-labelled anti-goat IgG; lanes with control slices 
were loaded with twice the amount of protein, except in the case of fluoranthene and 
1-methylphenanthrene. Figures above the immunoblots represent percentage values, 
corrected for amount of protein loaded, compared with control (DMSO-treated) slices 
which were set at 100%. 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
 
Figure 8: Concentration-dependent changes in CYP1B1 apoprotein levels in 
precision-cut rat lung slices incubated with PAHs. 
 
Precision-cut rat lung slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations (0-5 μM) for 48 hours. At the 
end of the incubation period, slices were removed from the media, microsomes 
prepared and proteins resolved by 10% (w/s) SDS-PAGE before being transferred 
electrophoretically to nitrocellulose paper. Immunoblot was carried out with anti-rat 
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CYP1B1 followed by peroxidase-labelled anti-goat IgG; lanes with control slices 
were loaded with twice the amount of protein, except in the case of fluoranthene, 
dibenzo[a,l]pyrene and 1-methylphenanthrene. Figures above the immunoblots 
represent percentage values, corrected for amount of protein loaded, compared with 
control (DMSO-treated) slices which were set at 100%. 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 9: Metabolism of 7-ethoxycoumarin by precision-cut human liver slices 
from two different donors. 
 
 
Precision-cut human liver slices from two donors were incubated with 7-
ethoxycoumarin (50 μM) for 6 hours, and metabolites were determined in the media. 
Results are presented as mean ± SD of triplicate slices. 
 
 
 
Figure 10: Concentration-dependent induction of ethoxyresorufin O-deethylase 
activity by PAHs in precision-cut human liver slices. 
 
Precision-cut human liver slices were incubated in the absence and presence of the 
various PAHs, dissolved in DMSO, at a range of concentrations (0-50 μM) for 24 
hours. At the end of the incubation period, slices were removed from the media, 
microsomes prepared and ethoxyresorufin O-deethylase (EROD) activity determined. 
Results are expressed as mean ± SD of triplicate pools of slices. 
* P<0.05; ** P<0.01; *** P<0.001 
 
 
Figure 11: Concentration-dependent changes in CYP1A1 apoprotein levels in 
precision-cut human liver slices incubated with PAHs. 
 
Precision-cut human liver slices were incubated in the absence and presence of the 
various PAHs, dissolved in DMSO, at a range of concentrations (0-50 μM) for 24 
hours. At the end of the incubation period, slices were removed from the media, 
microsomes prepared and proteins resolved by 10% (w/s) SDS-PAGE before being 
transferred electrophoretically to nitrocellulose paper. Immunoblot was carried out 
with anti-rat CYP1A1 followed by peroxidase-labelled anti-goat IgG; all lanes were 
loaded with 5 μg protein. Figures above the immunoblot represent percentage values 
compared with control (DMSO-treated) slices which were set at 100%. 
 
 
 
Figure 12: Effect of treatment with benzo[a]pyrene and β-naphthoflavone on rat 
hepatic and pulmonary CYP1B1 apoprotein levels. 
 
Rats received intraperitoneally a single dose of either benzo[a]pyrene or β-
naphthoflavone (25 mg/kg) and were killed 24 hours later. Solubilised hepatic and 
pulmonary microsomal proteins were resolved by 10% (w/s) SDS-PAGE before being 
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transferred electrophoretically to nitrocellulose paper. Immunoblot was carried out 
with anti-rat CYP1B1 followed by peroxidase-labelled anti-goat IgG; all lanes were 
loaded with 5 μg of protein. Figures above the immunoblots represent percentage 
values, corrected for amount of protein loaded, compared with control (DMSO-
treated) slices which were set at 100%. Lanes 1 and 4, control liver and lung 
respectively; lanes 2 and 5, β-naphthoflavone liver and lung respectively; lanes 3 and 
6, benzo[a]pyrene liver and lung respectively. 
 
 
 
Figure 13: Binding of PAHs to the Ah receptor. 
 
H1L1.1c2 cells were incubated with a range of concentrations of PAHs (10-12M – 
5x10-5M), dissolved in DMSO, for 24 hours at 37°C and 5 % CO2 in a humid 
environment. Binding to the receptor is expressed as % of TCDD binding (10-9 M). 
Results are presented as mean ± SD of triplicate determinations. 
 
 
Figure 14: Correlation between induction of ethoxyresorufin O-deethylase 
activity by PAHs in precision-cut lung and liver slices. 
 
 
Figure 15: Correlations between CYP1 induction potency of PAHs and 
molecular size. 
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